250 related articles for article (PubMed ID: 27232238)
1. Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
Herder M; Krahn TM
Healthc Policy; 2016 May; 11(4):70-81. PubMed ID: 27232238
[TBL] [Abstract][Full Text] [Related]
2. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
3. Investigating the landscape of US orphan product approvals.
Miller KL; Lanthier M
Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
[TBL] [Abstract][Full Text] [Related]
4. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
5. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
6. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
7. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
Rawson NSB
Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
[TBL] [Abstract][Full Text] [Related]
8. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
[TBL] [Abstract][Full Text] [Related]
9. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
Roberts EA; Herder M; Hollis A
CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
[No Abstract] [Full Text] [Related]
10. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
Thamer M; Brennan N; Semansky R
J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
[TBL] [Abstract][Full Text] [Related]
11. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
Macleod S; Lasko P; Mackenzie A
J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
[TBL] [Abstract][Full Text] [Related]
12. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
13. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
14. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.
Braun MM; Farag-El-Massah S; Xu K; Coté TR
Nat Rev Drug Discov; 2010 Jul; 9(7):519-22. PubMed ID: 20531273
[TBL] [Abstract][Full Text] [Related]
15. Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis.
Lexchin J
BMJ Open; 2018 Aug; 8(8):e023605. PubMed ID: 30166310
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Orphan Drug Indications: 2010-2018.
Kimmel L; Conti RM; Volerman A; Chua KP
Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicines' Impact on Orphan Drug Designation.
Mueller CM; Rao GR; Miller Needleman KI
Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
[TBL] [Abstract][Full Text] [Related]
18. Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis.
Lexchin J
Int J Health Serv; 2019 Apr; 49(2):294-305. PubMed ID: 30587064
[TBL] [Abstract][Full Text] [Related]
19. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
20. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
Lutz T; Lampert A; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]